US Stock MarketDetailed Quotes
ACHL Achilles Therapeutics
- 1.075
- +0.005+0.47%
Close Nov 29 13:00 ET
- 1.070
- -0.005-0.47%
Post 17:01 ET
44.17MMarket Cap-647P/E (TTM)
1.080High1.050Low22.61KVolume1.070Open1.070Pre Close24.07KTurnover0.11%Turnover RatioLossP/E (Static)41.09MShares1.76052wk High0.43P/B22.40MFloat Cap0.63052wk Low--Dividend TTM20.83MShs Float18.948Historical High--Div YieldTTM2.80%Amplitude0.630Historical Low1.064Avg Price1Lot Size
About Achilles Therapeutics Company
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
Company Profile
SymbolACHL
Company NameAchilles Therapeutics
Listing DateMar 31, 2021
Issue Price18.00
Founded2020
CEODr. Iraj Ali, PhD
MarketNASDAQ
Employees215
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address245 Hammersmith Road
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW6 8PW
Phone44-20-8154-4600
Websitehttp://achillestx.com
Company Executives
- Name
- Position
- Salary
- Dr. Iraj Ali, PhD
- Chief Executive Officer and Director
- 1.70M
- Robert Coutts
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Karl Peggs, M.D.
- Chief Medical Officer
- --
- Dr. Sergio Quezada, PhD
- Chief Scientific Officer
- --
- Dr. Edwin Moses, B.Sc. ,PhD
- Chairman of the Board
- 379.00K
- Julie ONeill
- Independent Director
- 102.00K
- Dr. Bernhard R.M. Ehmer
- Independent Director
- 106.00K
- Carsten Boess
- Independent Director
- 176.00K
- Dr. Michael F. Giordano, M.D.
- Independent Director
- 189.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data